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P-cadherin is a classical cell-to-cell adhesion molecule with a homeostatic function in several normal tissues. However, its
behaviour in the malignant setting is notably dependent on the cellular context. In some tumour models, such as
melanoma and oral squamous cell carcinoma, P-cadherin acts as a tumour suppressor, since its absence is associated with
a more aggressive cancer cell phenotype; nevertheless, the overexpression of this molecule is linked to significant tumour
promoting effects in the breast, ovarian, prostate, endometrial, skin, gastric, pancreas and colon neoplasms. Herein, we
review the role of P-cadherin in cancer cell invasion, as well as in loco-regional and distant metastatic dissemination. We
focus in P-cadherin signalling pathways that are activated to induce invasion and metastasis, as well as cancer stem cell
properties. The signalling network downstream of P-cadherin is notably dependent on the cellular and tissue context and
includes the activation of integrin molecules, receptor tyrosine kinases, small molecule GTPases, EMT transcription factors,
and crosstalk with other cadherin family members. As new oncogenic molecular pathways mediated by P-cadherin are
uncovered, putative therapeutic options can be tested, which will allow for the targeting of invasion or metastatic
disease, depending on the tumour model.
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P-cadherin was described for the first time in 1986, as
part of “a novel class of cadherins that appeared in de-
veloping mouse embryos” and its name is derived from
the site where this adhesion molecule was firstly charac-
terized, the placenta [1]. Embryonic histogenesis studies
have shown that P-cadherin expression is confined to
the extra-embryonic ectoderm and visceral endo-
derm, the structures originating the placenta in mice
[2]. P-cadherin is a calcium dependent cell–cell adhesion
glycoprotein, which has a crucial role in the conservation
of the structural integrity of epithelial tissues. Similarly to
other members of the cadherin family, P-cadherin regu-
lates several cellular homeostatic processes that participate
in embryonic development and maintain adult tissue
architecture, being important for cell differentiation, cell
shape, cell polarity, growth and migration [3–5]. Sharing
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and it is far less characterized [6, 7].
Despite being expressed in human foetal structures
[6, 8], P-cadherin is present in several adult tissues, usu-
ally co-expressed with E-cadherin, such as the basal layer
of the epidermis, the breast and the prostate, as well as
the mesothelium, the ovary, the cervix, the hair follicle,
and the corneal endothelium [1, 9]. Despite its role in the
maintenance of tissue architecture [10, 11], P-cadherin is
notably involved in disease states, namely in specific her-
editary genetic disorders and in cancer.P-cadherin in physiology: role in stem cell biology,
cell differentiation, and tissue architecture
P-cadherin contributes to the biology of stem cells of
the normal mammary gland and the hair follicle, and
its presence has been reported in embryonic stem
cells [6, 11–13]. Mammary fractionation experiments in
mice have shown that P-cadherin is found in a subpopula-
tion of cells with a basal-like phenotype, co-expressed with
SLUG, a transcription factor that regulates cadherin genes
and the genes involved in mammary epithelial cell lineages
[14]. In fact, P-cadherin expression is confined to the basalarticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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eventually contributing to the suprabasal stem cell niche
[15–17]. In the developing gland, P-cadherin is found in
stem cells that give rise to the myoepithelial cell layer,
termed cap cells [18, 19]. In contrast, in the mature lactat-
ing gland, P-cadherin is expressed in human alveolar cells,
the units responsible for milk protein production [20]. In
fact, a soluble form of P-cadherin corresponding to the
extracellular domain is found in human breast milk [20].
Although the significance of this soluble P-cadherin
fragment is not yet clarified, putative roles implicated in
immunological response and cell signalling have been
suggested.
In the growing hair follicle, P-cadherin is found in the
small hair placodes, specifically in the early progenitor
cells from hair germs, co-expressed with K14+ and α6-
integrin/CD49f + markers, where it has a putative role in
the differentiation of the growing hair follicle [13]. Fur-
thermore, it was shown that P-cadherin is one of the cell
surface proteins that allows the identification of the
pluripotent population of human embryonic stem cells,
being co-expressed with E-cadherin in this setting [12].
The function of P-cadherin has been significantly elu-
cidated by P-cadherin inactivation studies performed in
mice, as well as by data provided by P-cadherin germline
mutations in humans. Radice and colleagues demon-
strated that whole body deletion of P-cadherin disturbs
normal mammopoiesis, as CDH3/P-cadherin-null female
mice exhibit precocious mammary gland differentiation
in the virgin state, with extensive alveolar differentiation.
Moreover, these animals show increased risk of develop-
ing pre-neoplastic lesions, such as alveolar hyperplasia
and ductal dysplasia with increasing age. These observa-
tions indicate that P-cadherin cell-cell interactions and
signalling are important for limiting the growth of the
mature luminal epithelial cells, being important for the
maintenance of an undifferentiated state of the normal
mammary gland, which points to the role of P-cadherin
as a stem cell marker and active in modulating stem sig-
nalling pathways [21, 22].
Recent studies have clarified that P-cadherin ex-
pression is crucial to the maintenance of normal breast
epithelial architecture. LaBarge’s group has used an anti-
body that specifically antagonizes P-cadherin cell-cell
interactions in an in vitro self-organizing assay of the
human mammary bilayer to show that the migration of
mammary myoepithelial cells, occurring during normal
sorting of both layers, was compromised [23]. Further-
more, using mammary cells isolated from P-cadherin
knock-out mice, Andrew Ewald’s group has recently
demonstrated that the loss of P-cadherin causes pre-
cocious branching morphogenesis in matrigel and en-
hanced sustained dissemination into collagen type I,
pointing to the importance of this adhesion molecule inthe maintenance of normal breast epithelial architecture
[24]. It would be interesting to clarify the mechanisms
behind the homeostatic function mediated by P-cadherin
in the normal breast, since the loss of this adhesion mol-
ecule could cause the rupture of the myoepithelial cell
layer and lead to pre-neoplastic lesions. Future studies at
the cellular level should provide valuable information re-
garding the influence of P-cadherin in tissue architecture
and cell shape, namely crosstalk with cell polarity deter-
minants and other junctional proteins.
Although P-cadherin is not profusely expressed through-
out the body, this molecule is also found in other sites be-
sides the breast and hair follicle, namely in the basal layer
of many adult tissues, where it is believed to act as a clas-
sical cell-cell adhesion molecule, possibly contributing to
the undifferentiated state of epithelial cells. This is the
case for skin, prostate and testis, pancreas, several organs
of the digestive tract and urinary tract, lung and endomet-
rium. P-cadherin is completely absent from heart muscle
and brain [1, 9, 25].
In humans, loss of P-cadherin induces characteristic
genetic syndromes. Several CDH3/P-cadherin germline
mutations have been shown to cause P-cadherin func-
tional inactivation, leading to developmental defects
associated with hypotrichosis with juvenile macular
dystrophy (HJMD) [26–28] and ectodermal dysplasia,
ectrodactyly, and macular dystrophy (EEM syndrome)
[29, 30]. Sixteen CDH3 mutations have been associated
with HJMD, which is a rare recessive disorder, cha-
racterized by hair loss heralding progressive macular de-
generation and early blindness in the second to third
decade of life. These mutations mainly disturb the Ca2+
binding and the cadherin domain or result in the synthe-
sis of a truncated form of P-cadherin or in the absence
of P-cadherin expression [26–28, 31–37]. EEM is an-
other P-cadherin developmental defect associated syn-
drome, which is also characterized by sparse hair and
macular dystrophy of the retina as HJMD, with the
additional finding of split hand/foot malformation [29].
Different degrees of absence of bone structures, as well
as syndactyly, have been described, the hands often be-
ing more severely affected than the feet. Kjaer and col-
leagues first established the link between families with
EEM and homozygous mutations in CDH3/P-cadherin
gene in affected individuals and, up to now, three CDH3
gene mutations have been shown to lead to EEM syn-
drome [29, 30].
P-cadherin as a double edge sword: a tumour
suppressor or a tumour-promoting molecule?
Concerning carcinogenesis, the effective role of P-cadherin
remains an object of debate, since it can behave differently
depending on the molecular context and tumour cell
model studied (Table 1). In melanoma, non-small cell lung
Table 1 P-cadherin expression in primary tumours and its relevance in malignancy. The tumour promoting or tumour suppressive
effects associated with P-cadherin expression is dependent on the cellular and tissue context
Malignancy Expression in neoplastic tissue/cells
in comparison to normal tissue/cells
Behaviour References
Breast cancer Up-regulation Tumour promoting Paredes et al., 2005 [53]
Gastric cancer Up-regulation Tumour promoting Shimoyama et al., 1991 [54]
Endometrial cancer Up-regulation Tumour promoting Moreno-Bueno et al., 2003 [55]
Stefansson et al., 2004 [56]
Ovarian cancer Up-regulation Tumour promoting Patel et al., 2003 [57]
Pancreatic cancer Up-regulation Tumour promoting Taniuchi et al., 2005 [58]
Basocellular and squamous
carcinoma of the skin
Up-regulation Tumour promoting Wakita et al.,1998 [59]
Hardy et al., 2002 [60]
Cholangiocarcinoma Up-regulation Tumour promoting Obama K et al., 2005 [111]
Colorectal carcinoma Up-regulation Tumour promoting Hardy et al., 2002 [60]
Imai et al., 2008 [9]
Sun et al., 2011 [71]
Down-regulation Tumour suppressive Van Marck et al., 2011 [39]
Bladder cancer Up-regulation Tumour promoting Wang et al., 2014 [41]
Down-regulation Tumour suppressive Mandeville et al., 2008 [38]
Van Marck et al., 2011 [39]
Prostate cancer Up-regulation Tumour promoting Arenas et al., 2000 [42]
Down-regulation Tumour suppressive Jarrard et al., 1997 [40]
Melanoma Down-regulation Tumour suppressive Fenouille et al., 2012 [92]
Van Marck et al., 2005 [43]
Jacobs et al., 2011 [44]
Non small cell lung cancer Down-regulation Tumour suppressive Smythe et al., 1999 [45]
Oral squamous cell carcinoma Down-regulation Tumour suppressive Lo Muzio et al., 2004 [47]
Muñoz-Guerra et al., 2005 [48]
Hepatocellular carcinoma Down-regulation Tumour suppressive Bauer R et al., 2014 [52]
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carcinoma, P-cadherin has a similar tumour suppressive
behaviour to E-cadherin. However, in some tumour
models, such as bladder, prostate and colon carcinomas,
opposing effects have been found for P-cadherin, with
some studies pointing to an associated tumour suppres-
sive effect [38–40] and others pointing to the induction of
aggressive behaviour [39, 41, 42], with the differences
observed being related to the cell model, the immunode-
tection method, and the different functions attributed to
P-cadherin in the membrane or in the cytoplasm. The
pathology studies presented in this review focus in the
membranous expression of P-cadherin. However, one
important study that highlights the crucial issue of
P-cadherin expression in cytoplasm vs. membrane was
published by Mandeville and colleagues that showed that,
in bladder carcinomas, the patients with membrane ex-
pression of P-cadherin showed a longer cancer-specific
survival than the patients with cytoplasmic relocation of
P-cadherin [38].
Studies from Bracke and colleagues have shown an in-
vasion suppressor role for E-cadherin and P-cadherin onmelanoma, which decrease their membranous expres-
sion when the disease progresses to a metastatic stage
[43, 44]. De novo expression of P-cadherin in melanoma
cells reduced xenograft tumour growth and prolonged
mouse survival in a model mimicking micrometastatic
spread [44], as well as promoted adhesive cell-cell con-
tacts and anti-invasive effects in vitro. This response was
abolished when targeted mutations on the P-cadherin
intracellular juxtamembrane domain or on its extracellu-
lar domain were introduced [43].
In lung carcinoma, a similar adhesive and tumour sup-
pressive function was described for P-cadherin: in non-
small cell carcinoma, a decrease in its expression was
noted in 68 % of the patients [45]. Accordingly, the
transfection of P-cadherin in the cellular model of Lewis
lung carcinoma significantly increased cohesiveness of
cancer cells and greatly reduced invasion [46].
Furthermore, absence of P-cadherin expression con-
stitutes a hallmark of aggressive biological behaviour in
oral squamous cell carcinoma (OSCC). P-cadherin was
found to be downregulated in high grade OSCC and pa-
tients with tumours showing reduced or no P-cadherin
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free survival rates than the group of P-cadherin-expressing
tumours [47, 48]. Enhanced presenilin-1/γ-secretase
expression in OSCC cell lines was found to lead to accu-
mulation of P-cadherin in the cytoplasm and to reduced
cell-cell adhesion of OSCC cells [49]. In OSCC cells,
P-cadherin is able to interact with Wnt-related signalling
molecules, namely the Robo-3/Slit-2 complex, being re-
sponsible for the inhibition of cellular migration [50]. Fur-
thermore, it was shown that P-cadherin epithelial features
in OSCC are triggered by GSK-3β-mediated inactivation
and cytoplasmatic translocation of Snail [51].
In hepatocarcinoma, downregulation of P-cadherin
was found to induce aggressive behaviour, being corre-
lated to high-grade neoplastic lesions. Further, suppres-
sion of P-cadherin expression in hepatocarcinoma cells
in culture increased cell proliferation [52].
In contrast to the models presented above, aberrant
expression of P-cadherin associated with aggressive
tumour behaviour is observed in breast [53], gastric [54],
endometrial [55, 56], ovarian [57], prostate [42], pancre-
atic [58], bladder [41] and colorectal carcinomas [9], as
well as in basocellular and squamous carcinomas of the
skin [59]. Importantly, P-cadherin appears upregulated
in the earlier stages of the malignant progress in most
cases [60, 61]; however, the extent to which P-cadherin
contributes to the carcinogenesis or the progression of
these various tumours is still not clarified.
It is in breast cancer that this adhesion molecule has re-
ceived more attention and the mechanisms leading to the
major tumour promoting effects have been widely charac-
terized. P-cadherin aberrant expression is associated with
breast carcinomas of high histological grade, as well as
with the expression of well established markers associated
to poor patient prognosis, like Ki-67, EGFR, CK5, vimen-
tin, p53 and HER-2, and negatively associated with the ex-
pression of hormonal receptors (ER and PgR) [53, 61–64].
In fact, P-cadherin overexpression is mainly found in the
triple-negative and basal-like subgroup of breast cancers
[65, 66] and it is strongly correlated with the presence of
BRCA1 mutations [67]. Interestingly, none of these re-
ports showed a significant association with tumour size
and lymph node metastasis.
P-cadherin overexpression is associated with
cancer cell invasion and metastatic dissemination
The relevance of P-cadherin in metastasis has been ad-
dressed by the analysis of clinicopathological data in pri-
mary tumours and matched lymph node metastasis,
animal models of metastatic dissemination, and cell
culture experiments using metastatic cellular models
(Table 2).
The association of P-cadherin expression in the pri-
mary tumour with lymph node involvement varies, withsome reports pointing to a positive association, like in
gallbladder adenocarcinoma [68], and others showing no
significant association, such as in breast cancer [53].
Agnieszka and colleagues, by the use of a series of
human breast carcinomas with matched lymph node
metastasis, showed that P-cadherin expression varied
considerably (increased or decreased) between primary
tumour and nodal metastasis (29.2 % of total cases), and
that all the primary cases with P-cadherin enhancement
in the lymph nodes were triple negative breast carcin-
omas (i.e., breast carcinomas that are negative for ER,
PR and HER2). Importantly, a low variation in staining
intensity was found for ER, PR, HER2, CK5/6 and EGFR
expression in the primary tumour and nodal metastasis
(over 90 % of the cases showed the same level of expres-
sion for these markers), suggesting that P-cadherin may
be a candidate prognostic biomarker to explore in the
lymph nodes [69].
Using a model of human ovarian cancer metastasis, in
which Caov-3 cells were intraperitoneally injected in nude
mice, forming multiple secondary tumours on the mesen-
terium and small bowel, Cheung and colleagues showed
that P-cadherin silencing leads to a significant decrease in
the number of metastatic cells present in the ascitic fluid.
The ascites volume and formation of tumour nodules were
substantially decreased by β1 integrin and P-cadherin silen-
cing, suggesting that these molecules might be involved in
the adhesion of metastatic cells to the peritoneum [70].
In colon cancer, gene expression and immunohistochem-
istry analyses showed that P-cadherin expression was sig-
nificantly higher in liver metastases than in paired primary
colorectal cancer tumours. Knockdown of P-cadherin in
colon cancer cells inhibited wound healing, proliferation,
and colony formation and resulted in developing fewer
liver metastatic foci in vivo. The effect of P-cadherin inhib-
ition was associated with the down-regulation of β-catenin
(βctn) and its downstream target molecules, including sur-
vivin and c-Myc [71].
P-cadherin expression in carcinomatous prostate is in-
creased compared to normal prostate tissue [42] and this
was significantly associated with bone metastasis [72].
Importantly, the migratory and invasive phenotype of
prostate cancer cells was dependent on P-cadherin ex-
pression [73, 74].
In breast cancer, we found that overexpression of
P-cadherin promotes cell motility, cell migration, as well
as invasion capacity through matrigel [75]. A similar ag-
gressive phenotype was also observed in bladder and pan-
creatic cancer cell lines [38, 39, 58]. Curiously, we have
noticed that P-cadherin is able to induce invasion only in
breast cancer cells that already express an endogenous
and functional E-cadherin molecule [75–77]. In fact,
breast carcinomas that co-express E- and P-cadherin show
a patient survival that is worse than that associated with
Table 2 P-cadherin expression in invasion and metastasis and the corresponding signalling pathways. This table focuses on the
major tumour promoting signalling effects mediated by P-cadherin in the metastatic setting
Metastatic site Phenotype Signalling Ref.
Breast cancer Lymph nodes Significant change of P-cad expression in
the lymph nodes vs. primary tumour
Adamczyk et al.,
2012 [69]




α6β 4-integrin, FAK, Src, Akt Vieira et al., 2012
and 2014 [16, 17]
Increased glycolysis and acid resistance CA-IX, Glut-1 Sousa et al.,
2014 [94]
Ovary Peritoneum P-cad necessary for adhesion of CaOV-3 cells
to the peritoneum
P-cad/β 1-integrin Ip et al., 2014 [85]
Peritoneum P-cad necessary for adhesion of CaOV-3 and
OVCAR-3 (to ECM and peritoneal cells) P-cad
inhibition attenuated tumour growth, ascites
formation, and the number of metastatic
implants
Gonadotropin-releasing hormone induces




Peritoneum P-cad necessary for the activation of the
IGF-1R by GnRH in CaOV-3 cellsP-cad and
p-IGF-1R coexpression was significantly
stronger in metastasis compared with
primary tumours
p120 phosphorylation by Gonadotropin-
releasing hormone is dependent on
P-cadherin and IGF-1R interaction
Cheung et al.,
2011 [86]
Colon Liver Increased in liver metastasis of colon cancer,
compared with the primary cancer tissue;
Knock-down of P-cadherin in colon cancer
cells (LOVO) resulted in developing fewer
liver metastatic foci
P-cad inhibition in colon cancer cells (LOVO)
induced the up-regulation of E-cadherin and
the down-regulation of β-catenin and its




Prostate cancer Bone P-cad expression in primary tumour associated





Lymph nodes P-cad expression in primary adenocarcinoma
and squamous cell/adenosquamous carcinoma
associated with lymph node metastasis
Yi et al.
2014 [68]
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herins or that do not express any of these adhesion
molecules [58, 77].
A study by Sarrió and colleagues showed that when ei-
ther P- or E- cadherin was expressed alone in a breast
cell line that is negative for both cadherins, a similar
gene expression pathway was activated, followed by the
acquisition of a epithelial morphology and increased
cell-cell adhesion. This suggests that P-cadherin per se is
not enough to increase cancer aggressiveness in breast
cancer and that when either P- or E-cadherin are ex-
pressed alone, both proteins act as suppressors of cancer
properties [78]. However, this study did not analyse the
cellular system where both E- and P-cadherin are co-
expressed in the same cells, resembling the more fre-
quent breast carcinomas in which aggressive invasion is
observed when P- and E-cadherin are jointly expressed
[79]. In this case, it has been proposed that the un-
derlying mechanism leading to P-cadherin mediated
tumour promoting properties comprises the perturb-
ation of the tumour suppressive signalling mediated by
E-cadherin [79].The reports mentioned above clearly show the
importance of studying the mechanisms mediated by
P-cadherin that lead to the metastatic dissemination of
cancer cells. These mechanisms may include changes in
cadherin mechanotransduction, stem cell signalling, cad-
herin switching and epithelial to mesenchymal transition.
Further, the tumour microenvironment and the crosstalk
with non-tumour cells in the secondary site must also be
considered.
P-cadherin signalling pathways in invasion and
metastasis
For the last two decades, most of the signalling
described for P-cadherin has been derived from its
oncogenic behaviour, with aberrantly elevated levels of
P-cadherin playing a critical role in the augmentation of
neoplastic signalling networks and in the further acquisi-
tion of aggressive tumour phenotypes (Fig. 1). In a clas-
sical perspective, P-cadherin mediates its intercellular
signalling through the interaction with βctn and p120ctn
molecules, which contribute to the stabilization of the
adherens junction complex at the cell surface, allowing
Fig. 1 P-cadherin signalling pathways in the malignant setting. The tumour promoting effects mediated by P-cadherin include cell invasion, cell
motility, stem cell activity and metastases formation in different tissue contexts (see text for details). (GnRH – Gonadotropin-releasing hormone;
GnRHr - Gonadotropin-releasing hormone receptor; IGF-1R – Insulin-like growth factor receptor; MMP – matrix metalloproteinase; EGFR – epidermal
growth factor receptor)
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have recently demonstrated that P-cadherin is able to inter-
fere with the tumour suppressive function of E-cadherin in
breast carcinomas and in cell culture, promoting cancer cell
invasion by disrupting the interaction between E-cadherin
and both p120ctn and βctn [79]. In fact, the breast carcin-
omas that co-express both adhesion molecules have a de-
crease in the membrane staining of p120-catenin (p120ctn)
and an increase in the cytoplasmic localization for this
protein [58, 77]. In pancreatic and ovarian cancer, it
was shown that p120ctn, once in the cytoplasm, can ac-
tivate Rho-GTPases, like Rac1 and Cdc42, altering the
actin cytoskeleton polymerization and promoting cell
motility [58, 80]. In the absence of E-cadherin expression,
P-cadherin is able to suppress invasion by its strong inter-
action with catenins, in a similar way as E-cadherin in
cell-cell adhesion [79]. Further, a recent report by
Bazellieres and colleagues showed that both cadherins are
able to compete for a joint mechanotransduction pathway
in normal breast cells, showing that P- and E-cadherinplay fundamentally distinct roles in controlling force
transmission at intercellular junctions [81]. They suggest
that P-cadherin is involved in increasing the levels of
intercellular tension within a monolayer of MCF10A
breast cells, whereas E-cadherin dictates the rate at which
the intercellular tension builds up over time. The authors
showed that in the absence of E-cadherin, P-cadherin is
able to take over its role as a tension regulator, triggering
mechanotransduction and preventing a decrease in inter-
cellular tension, thus confirming at the mechanical level
that where only P- or E-cadherin are expressed, these pro-
teins act as suppressors of cancer invasion.
Transient or irreversible inactivation of the cadherin-
catenin complexes by secreted factors, such as metallopro-
teinases (MMPs), produced by tumour and/or stromal
cells can also occur. We have shown that P-cadherin over-
expression promotes cell invasion, migration and motility
accompanied by the secretion of MMP1 and MMP2,
which lead to P-cadherin ectodomain cleavage, releasing
the soluble P-cadherin fragment [75]. Further studies are
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in breast cancer is exclusive for P-cadherin or this
function can also be played by E-cadherin. Still, it is im-
portant to highlight that in this study the cellular context
was E-cadherin positive.
Studies in breast and ovary carcinomas have demon-
strated the connection between P-cadherin and the
activation of integrin molecules, which gives cancer cells
an advantage to attach to the underlying extracellular
matrix. Our group has demonstrated an important inter-
play between P-cadherin and α6β4 integrin in breast
cancer, which is linked with increased cancer cell adhe-
sion to the basemement membrane substrate laminin.
We showed that P-cadherin downstream signalling in
response to laminin involves the activation of FAK, Src
and AKT kinases, an association that was validated
in vivo [16]. Although a direct link with metastatic
dissemination was not established, the α6β4 integrin
heterodimer was shown to be important for cell invasion,
as well as for the maintenance of stem cell properties.
In the breast, the link of α6β4-integrin and P-cadherin
is exclusive for P-cadherin and no such link was found
for E-cadherin. However, in other contexts there seems
to be crosstalk between α6β4-integrin and the classical
E- and P-cadherin molecules. In premalignant lesions of
skin tumours, P-cadherin and α6β4-integrin are over-
expressed and the expression of E-cadherin is down-
regulated [82], whereas in prostate cancer and in oral
squamous cell carcinoma, E-cadherin and β4-integrin are
markedly loss in primary and metastatic lesions, although
the mechanistic pathways were not explored [83, 84].
Moreover, in ovarian cancer, P-cadherin is required for
the maturation of β1 integrin in a mechanism that de-
pends on p120ctn expression, leading to the subsequent
promotion of peritoneal adhesion of metastatic cells
[85]. In fact, P-cadherin and β1 integrin are induced, to-
gether with α2 and α5 integrins, by the prometastatic
gonadotropin-releasing hormone (GnRH) leading to the
preferential adhesion of ovarian carcinoma cells to
collagen type-I and laminin. In this context, P-cadherin
inhibition using RNAi leads to a decrease in cancer cell
peritoneal attachment and in the number of metastatic
ovarian cancer foci, suggesting that P-cadherin is involved
in the early stages of metastatic cell adhesion [70].
It was also demonstrated that P-cadherin activates migra-
tion and invasion of ovarian cancer cells through IGF-1R.
Cheung and colleagues found that the GnRH metastatic
behaviour was shown to depend on P-cadherin expression,
which in turn controls the activation of IGF-1R and the
phosphorylation of p120ctn and its cytoplasmic loca-
lization [86]. P-cadherin and p-IGF-1R were significantly
co-expressed in peritoneal metastatic lesions compared
with paired primary ovarian tumours and, in ovarian can-
cer cells; GnRH induces the recruitment and formation ofan IGF-1R/P-cadherin complex. P-cadherin regulation
of p120ctn is IGF-1R-dependent, since the silencing
of IGF-1R no longer caused GnRH-induced phosphor-
ylation of p120ctn in P-cadherin overexpressing cells
[86]. Furthermore, the same group showed that GnRH
is an inducer of E- to P-cadherin switching, which is
a crucial step during ovarian tumorigenesis, particu-
larly in metastasis [80].
Human breast tumours that depend of nitric oxide
(NO) oncogenic signalling are linked to poor patient
survival and P-cadherin overexpression. Switzer and col-
leagues demonstrated that P-cadherin is a NO-inducible
gene in ER-negative breast cancer cells. This mechanism
involves the activation of Ras/MEK/ERK signalling
pathway by NO, which in turn leads to the activation of
Ets-1, a transcription factor that is implicated in metas-
tasis, tumour progression and causes P-cadherin up-
regulation [87]. Furthermore, it was shown that NO
treatment led to decreased E-cadherin and decreased
cell adhesion indicating that NO signaling may be in-
volved in a EMT of ER-negative breast cancer cells [88].
The Wnt/βctn signalling pathway is a known pathway
associated with cadherin molecules [89] and the Wnt/
βctn oncogenic effects derived from P-cadherin aberrant
expression have been reported in colon cancer cells.
P-cadherin knock-down in these cells reduced cell motil-
ity and proliferation, as well as decreasing cancer cell
growth, invasion and liver metastasis in nude mice. These
effects were associated with a reduction of βctn expression
and Wnt responsive genes, including c-myc and survivin
in vitro. This phenotype was also associated with a cad-
herin switch, since P-cadherin inhibition was accompanied
by E-cadherin up-regulation [71].
Elevated levels of P-cadherin that occur in early oral
tumour development play a critical role in neoplastic
signalling networks. The ligand-dependent signalling of
IGF-1R and EGFR is potentiated by P-cadherin in cell
models or early tumour development. In fact, P-cadherin
prolongs the activation of the mitogen-activated protein
(MAP) kinase in malignant and dysplastic cells and
increases the magnitude of AKT phosphorylation in dys-
plastic cells. P-cadherin overexpression alone is sufficient
to increase steady-state levels of the mesenchymal tran-
scription factor Snail and increase cell motility in dys-
plastic cells [90].
In the rabdomyosarcoma context, P-cadherin is neces-
sary for the migratory and invasive potential of alveolar
cells. In these cells, P-cadherin was shown to be a direct
transcriptional target of both Pax3 and Pax3/7-FOXO1A.
Further, P-cadherin overexpression in myoblasts led to a
reduction in the expression and mislocalization of the
classical muscle cadherins, N- and M- cadherins, thus
favouring a cadherin switching, which is a hallmark of
metastatic progression [91].
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port that the metastatic malignant melanocytes down-
regulate P-cadherin expression and acquire a migratory
phenotype as the result of SLUG expression, a mela-
nocyte lineage transcription factor that was shown to
downregulate this junctional protein. Furthermore, a
role for SPARC in the activation of PI3K/Akt signalling,
which in turn activates SLUG and predisposes to melan-
oma metastasis was shown in this model [92].
P-cadherin and cancer stem cell activation
Studies show that P-cadherin contributes to the survival
of aggressive cancer cells. In light of the cancer stem cell
(CSC) hypothesis, these cells often exhibit stem like
properties, which allow them to resist to standard cancer
therapies causing tumour relapses and metastasis in can-
cer patients [93]. Our group has shown that P-cadherin
is directly associated with the expression of the breast
stem cell markers CD44, CD49f and the activity of alde-
hyde dehydrogenase in human breast carcinomas and in
a series of breast cancer cell lines. Moreover, cell po-
pulations depleted for P-cadherin expression showed
decreased in vitro self-renewal capacity, lower ability to
grow colonies in 3D matrigel cultures and reduced
tumourigenicity in nude mice. Importantly, an associ-
ation was found between P-cadherin and the luminal
progenitor phenotype of the normal breast differenti-
ation hierarchy: CD49f + CD24+ [17]. Furthermore, we
showed that P-cadherin is essential for the adhesion of
cancer cells to extracellular matrix substrates that are
critical for metastatic dissemination, namely laminin,
vitronectin and fibronectin. Interestingly, the α6β4 integ-
rin heterodimer was implicated in stem cell activity and
signalling cascade downstream of P-cadherin in response
to laminin, namely in the activation of FAK and Src [16].
Although the role of CSCs and P-cadherin in the
metastasis needs to be further clarified, we believe that
P-cadherin, as well as α6 and β4 integrin receptors, pos-
sibly in combination with other CSC markers, could be
explored to better define the CSC phenotype of breast
carcinomas or other malignant tumours and their corre-
sponding metastasis.
An important link was established between P-cadherin
and CSC metabolism. CSCs are hypoxia-resistant and
present a preponderant glycolytic metabolism. We have
demonstrated that aberrant P-cadherin expression is as-
sociated with the hypoxic/glycolytic and acid-resistant
phenotype in invasive breast carcinomas, represented by
a panel of markers including HIF-1α, GLUT1, CAIX,
MCT1 and CD147. In vitro, HIF-1α stabilization was
accompanied by increased membrane expression of
P-cadherin and P-cadherin silencing led to a decrease
of the mRNA levels of GLUT1 and CAIX and de-
creased mammosphere-forming efficiency [94]. P-cadherin expression shifts the metabolic program of
these cells, being responsible for tumour aggressive-
ness and cell survival. This study was performed in a
cellular context that was E-cadherin positive, but the
contribution of E-cadherin in this signalling response
was not explored.
A number of hypotheses have been proposed to justify
the anomalous expression of P-cadherin by breast CSCs,
namely, the oncofetal properties of P-cadherin protein
[54], its histogenetic origin in cap cells [19] or the acqui-
sition of a stem cell like phenotype [17]. However,
although P-cadherin positive carcinomas seem to have a
myoepithelial/basal-like transcriptomic programme, which
points to a putative role in the cancer stem cell niche, it
remains unclear which molecular mechanisms lead to the
activation of P-cadherin during epithelial transformation.
Several studies identify the stem cell transcription factors
βctn, C/EBP-β and p63 as able to induce P-cadherin ex-
pression [95–97]. We showed that P-cadherin is expressed
in cells displaying the luminal progenitor phenotype of the
normal breast [17] and, notably, BRCA1 mutation carriers
exhibit an increased luminal progenitor cell population
[98]. In fact, the BRCA-1 gene is a well-known inducer of
luminal cell differentiation [99] and a transcriptional re-
pressor of basal-like genes, including P-cadherin [100]. It
is still unclear whether the overexpression of P-cadherin
in the BRCA-1 inactivated basal-like breast carcinomas is
related to the transformation of the luminal progenitor,
which is the cell-of-origin that has been described for this
malignancy [101, 102].
The metastatic dissemination of cancer cells relies on
signalling pathways that are often activated in CSCs self-
renewal [93], specifically the Wnt, Notch and Hedgehog
pathways. The Wnt signalling pathway which is also
responsible for the pluripotency of mammary stem cells
[103], was found to be activated and correlated with
P-cadherin expression in colon cancer cells, as men-
tioned previously [71]. The possible crosstalk between
P-cadherin, notch and hedgehog signalling remains to
be elucidated in tumours, as well as in metastasis.
P-cadherin: is it a putative therapeutic target
in cancer?
Targeting P-cadherin in cancer may be a good thera-
peutic approach, since normal tissues usually express
very low levels of this cadherin [9]. Patients with primary
tumours that overexpress P-cadherin are potential candi-
dates for therapy regimens targeting this molecule. For
this therapy to succeed, P-cadherin aggressive signalling
pathways, which can be context-specific, must be scruti-
nized. Importantly, some studies have already pointed to
a direct inactivation of P-cadherin as a therapeutic
approach. Imai and colleagues reported a cancer im-
munotherapy study using cytotoxic T cells specific to
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fects. The authors proposed that this could provide and
effective anticancer approach for pancreatic, gastric and
colorectal cancers [9]. Endo and colleagues showed that
one anti-P-cadherin mouse monoclonal antibody used in
radioimmunotherapy significantly suppressed lung cancer
growth [104]. In fact, a novel and highly selective human
monoclonal antibody against P-cadherin (PF-03732010,
Pfizer) has demonstrated significant anti-tumour and anti-
metastatic activities in distinct P-cadherin-overexpressing
tumour models, which included breast, gastric, lung,
prostate and colon carcinomas, without introducing any
adverse secondary effects in mice [105, 106]. PF-03732010
also reduced lymph node metastases and lowered the
levels of circulating tumour cells in whole blood of
P-cadherin-positive tumour bearing mice. The anti-
metastatic property of the antibody was remarkable, since
it significantly inhibited tumour cell infiltration into the
lungs [106]. In an attempt to reach the full potential for
clinical development of the antibody, PF-03732010 has
completed a phase I clinical trial. The report from this first
clinical trial [107] shows that, in spite of the anti-tumour
effects of PF-03732010 in animal models, it was not pos-
sible to observe any clear beneficial effect in humans.
However, because the participants did not experience any
toxicity with the antibody, the effective therapeutic dose
and its toxicity were undetermined. A new planning of the
pharmacokinetic and pharmacodynamic studies in hu-
mans treated with antibodies against P-cadherin, with
stratification for the different carcinomas, should translate
in clearer results. Recent studies from our group also
point to the potential use of the anti-cancer protein azurin
in P-cadherin overexpressing breast cancer models.
Azurin is a bacterial peptide secreted by Pseudomonas
aeruginosa that leads to a decrease in the expression level
of P-cadherin its invasive effects and oncogenic signalling
[108, 109]. A phase I clinical trial showed evidence of
azurin anti-tumour activity in human neoplasias [110].
Conclusion
From the studies mentioned in this review, it is clear that
despite P-cadherin being a classical adhesion molecule
with regulatory functions in the normal context, there is a
significant association between the overexpression of this
molecule and poor prognosis in the carcinomas of the
breast, prostate, ovary, colon and stomach. The major sig-
nalling pathways downstream of P-cadherin are context
specific and include the crosstalk with α6β4 integrin, Src,
Wnt, EGFR, and the interaction with other cadherin
family members. Clarifying the P-cadherin signalling net-
works, as well as dissecting novel oncogenic pathways, is
fundamental to uncover potential therapeutic targets that
will counteract the effects of this protein in the invasion
and the metastatic dissemination.Abbreviations
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